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ABSTRACT 
Introduction: In the United States, hepatitis C virus (HCV) is the most common bloodborne infection with 
an estimated prevalence of 3.2 million people. Although new cases of HCV have been declining since the 
1980s there are still approximately 17,000 new cases diagnosed each year. HCV infection has become 
the most frequent reason for hepatologic consultation and the single leading indication for hepatic 
transplantation, accounting for 30% of such procedures in the United States. Until late 2013, the 
treatment of choice for chronic HCV was pegylated interferon-α plus ribavirin, which achieved a cure rate 
of 54%-63%. Recently, novel antiviral drugs that specifically target HCV have provided better options in 
HCV treatment. Use of ledipasvir, an HCV NS5A replication complex inhibitor in combination with 
sofosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, in patients with chronic HCV, achieves 
high rates of sustained viral response (SVR) with just 12-weeks of treatment.  
 
Methods: This prospective cohort study represents a collaboration between James Madison University 
and the Harrisonburg-Rockingham Free Clinic. This is a pilot study including only 10 patients. Patients 
received a five fixed-dose combination of ledipasvir-sofosbuvir (90mg/400mg), or Harvoni®, for a total of 
12-weeks. During this time various physiologic parameters were measured to monitor ledipasvir-
sofosbuvir efficacy including liver function tests, complete blood counts, and HCV-RNA levels.  
 
Results: Patients experienced statistically significant decreases in ALT/AST values just 30 days after 
initiating treatment with ledipasvir-sofosbuvir and maintained this response throughout duration of 
therapy. Additionally, HCV RNA levels declined to undetectable levels in 60% of patients within 8 weeks 
of therapy.  
 
Discussion: This study is a work in progress, and patients will continue to be monitored for response to 
ledipasvir-sofosbuvir for at least 6 months after completions of HCV treatment. Improvements to consider 
would be improving study power by increasing the number of study participants and expand scope of 
research to include quality of life assessments. The results of this study are congruent with other 
published research on the efficacy of 12-weeks of ledipasvir-sofosbuvir However, this study has not yet 
reached an endpoint to evaluate the rate of HCV relapse associated with ledipasvir-sofosbuvir treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION: 
Epidemiology of Viral Hepatitis C Infection 
Chronic Hepatitis C virus (HCV) infection is one of the most common chronic liver diseases and 
results in thousands of deaths each year.1 There are six major genotypes (1-6) of HCV; with genotype 1 
being the most common and accounting for 70 to 80% of the hepatitis C cases in the United States.2 
Globally, areas with the highest prevalence of HCV include Central and East Asia, North Africa, and The 
Middle East.  The Asia Pacific, Latin America, and North America are among the places that were noted 
to have the least prevalence of HCV.1  
Hepatitis C can be separated into acute and chronic; however, 75% of patients with acute 
hepatitis C develop the chronic infection.2 The Centers of Disease Control and Prevention (CDC) estimate 
2.7 million people in the United States living with chronic hepatitis C virus.3 The CDC also states the 
infection is most prevalent among those born in 1945 to 1965, with the majority of this population being 
infected during the 1970s and 1980s which were when rates of HCV were the highest.3  
Table 13 is derived from statistics updated in the current year by the CDC showing the risk of 
developing chronic HCV, chronic liver disease, cirrhosis, and chronic infection resulting in death due to 
hepatitis C virus.   
Table 1: Of every 100 persons infected with HCV, approximately 
75–85 Will go on to develop chronic infection 
60–70 Will go on to develop chronic liver disease 
5–20 Will go on to develop cirrhosis over a period of 20–30 years 
1–5 Will die from the consequences of chronic infection (liver cancer or cirrhosis) 
75–85 Will go on to develop chronic infection 
Centers of Disease Control and Prevention: Updated October 2015 
  
Hepatitis C viral infection is primarily transmitted through large or repeated percutaneous 
exposures to infected blood such as injection drug use, receiving donated blood, blood products or 
organs, needlestick injuries in healthcare settings and birth to an HCV-infected mother.1,3  HCV can also 
be spread through sexual intercourse with an HCV-infected person, sharing razors or toothbrushes, or 
other health care procedures that involve invasive techniques.  Currently the most common means of 
transmission in the US is injection drug use with the sharing of needles.3,4   This accounts for 
approximately one third of young aged injection drug users (IDUs) that are HCV-infected and 
approximately 70-90% of older and former IDUs who also have hepatitis C virus.1,3  
 
Etiology  
Risk factors for infection with Hepatitis C Virus (HCV) in the United States include intravenous 
drug use, blood transfusion sex with an intravenous drug user, incarceration for more than three days, 
religious scarification, blood-carrying fomite exposure, piercings, and immunoglobulin injection.4 Overall, 
intravenous drug use is the most significant risk factor for HCV infection and also the most efficient means 
of transmission;3,4 According to a global systematic review of 77 countries intravenous drug use accounts 
for 60-80% of HCV transmission, with China, USA, and Russia having the largest populations at 1.6 
million, 1.5 million, and 1.3 million respectively.5  
Approximately 80% of patients in the United States with chronic HCV were born between 1945 
and 19653,6, however age of infection appears to be decreasing, with the largest increases occurring east 
of the Mississippi River.7 Data from the National Notifiable Disease Surveillance System for Kentucky, 
Tennessee, Virginia, and West Virginia for the period between 2006 and 2012 confirms a total of 1,377 
cases of acute HCV infection reported with 44.8% of these cases among persons aged ≤ 30 years old.7  
Approximately 70% of these individuals reported intravenous drug use as the principal risk factor,7 
suggesting a correlation between increased intravenous drug use and decreasing age of HCV infection. 
  
Pathophysiology  
Hepatitis C virus (HCV) was first cloned in 1989 and identified as the main causative agent of a 
disease previously known as post transfusion non-A, non-B hepatitis virus infection.8  HCV is an 
enveloped RNA virus belonging to the Hepacivirus of the family Flaviviridae.9  HCV has a sense-strand 
RNA genome that is composed of a highly conserved 5’-untranslated region (UTR), which includes an 
internal ribosome entry site, and open reading frame that encodes both structural and non-structural 
proteins, and a 3’-UTR.10  One non-structural protein of importance is the NS5B RNA dependent RNA 
polymerase (RdRp), an effective target for anti-HCV agents.11  Viral RdRp lack proof-reading function, 
which accounts for the high genetic variability of HCV.10  Of the nine genetically distinct HCV genotypes, 
genotype 1 is the predominant type in the United States, affecting 72% of patients with HCV infection.12   
HCV only infects humans and chimpanzees. Hepatocytes are the main target of HCV but 
infection of B cells, dendritic cells, and other cell types has also been reported.10 Circulating HCV 
particles can be associated with low and very-low density lipoproteins, and viral entry to hepatocytes may 
involve the low-density lipoprotein receptor, glycosaminoglycans scavenger receptor class B type-I and 
the tetraspanin protein CD81 and claudin-1 (CLDN1).13-15  CLDN1 functions to mediate incorporation into 
the hepatocyte, a process involving clathrin-mediated endocytosis.16  Infection with HCV triggers the non-
specific immune response involving type I interferon (IFN) secretion and natural killer cell activation.17  
Recent studies of liver samples from chimpanzees infected with HCV show that IFN-alpha inducible 
genes are broadly and rapidly induced, but that this response fails to control viral replication.18  The 
adaptive immune response occurs approximately 7-31 weeks after infection when anti-HCV antibodies 
are detectable. It is not known whether these antibodies play a role in viral clearance, but they may be 
capable of preventing HCV reinfection.19 Spontaneous HCV clearance is related to a sustained virus-
specific CD4+ T-cell response. This response is weak in individuals who develop chronic infection, and 
that this may be due to direct HCV infection of immune cells or modulation of function.20-22  
  
Clinical Diagnosis of Chronic Hepatitis C Infection  
Patients with chronic hepatitis C need to have a thorough history and physical exam that focuses 
on factors associated with accelerated disease progression.  The history should include questions 
regarding alcohol use, complications associated with fatty liver or underlying cirrhosis, and menopausal 
status (in women).  Also included would be factors that may affect their ability to qualify for antiviral 
therapy (cardiopulmonary disease, past or present psychiatric problems, autoimmune disease, and other 
comorbid conditions).23 The physical exam for these patients needs to evaluate for signs of advanced 
liver disease such as spider angiomata, palmar erythema, splenomegaly, jaundice or caput medusa.24  
People who develop HCV are usually asymptomatic, however, they may present with mild 
symptoms that are shown in Table 2.   Patients who develop symptoms will usually develop them within 
4-12 weeks after exposure to the virus.  It is noted that approximately 20 to 30% of newly infected 
individuals present with abdominal pain, jaundice, poor appetite and fatigue.3  The vast majority of 
patients with chronic HCV are also minimally symptomatic, however, in these patients the most common 
complaint is fatigue.25  Chronic hepatitis C may also be associated with lichen planus, mucocutaneous 
vasculitis, glomerulonephritis, porphyria cutanea tarda and possible non-Hodgkin B-cell lymphoma.2  
There are also several extrahepatic manifestations associated with chronic HCV that are listed in Table 
2.3,24-26  
  
Table 2 
Clinical Manifestations associated with 
Chronic HCV Infection 
Extrahepatic Manifestations associated with 
Chronic HCV Infection 
• Fatigue 
• Abdominal pain 
• Loss of appetite 
• Weight loss 
• Jaundice 
• Weakness 
• Fever 
• Nausea and Vomiting 
• Dark urine 
• Clay-colored stool 
• Myalgias and Arthralgias 
• Hematologic diseases, such as essential 
mixed cryoglobulinemia and lymphoma 
• Renal disease, particularly 
membranoproliferative glomerulonephritis 
• Autoimmune disorders, such as thyroiditis 
and the presence of autoantibodies 
• Dermatologic conditions, such as 
porphyria cutanea tarda and lichen planus 
• Diabetes mellitus 
 
  
         A thorough diagnostic lab work up is required for individuals with hepatitis C viral infection. These 
tests can be divided into two main categories:23 (1) Serologic assays that detect antibodies to hepatitis C 
and (2) Molecular assays that detect or quantify HCV RNA. 
Antibody testing can be done through a number of assays including the standard immunoassays.  
Several options are available for patients with chronic HCV including laboratory testing, rapid point of care 
testing, and home tests on specimens collected by the patient. To detect anti-HCV antibodies in serum 
and plasma the enzyme-linked immunosorbent assay (EIA or ELISA) is most commonly used in clinical 
laboratories.23,27  There has also been use of chemiluminescence immunoassays, which have shown to 
have performance that is comparable to the third generation EIAs.28  
Two essential tools in the diagnosis and management of individuals with chronic HCV are 
detection and quantification of HCV-RNA.  These assays are used to confirm the presence or absence of 
infection and to quantify the amount of HCV-RNA. Quantitative assays, such as the real time PCR 
(polymerase chain reaction) assay, are used before treatment to measure baseline HCV viral load and 
during treatment to assess therapy response.23,29  Likewise, qualitative tests are capable of detecting low 
levels of HCV-RNA to confirm the diagnosis of HCV infection and are also used to assess sustained 
virologic responses (SVR) to antiviral therapy.23,29  Both qualitative and quantitative tests will help pinpoint 
the amount of HCV-RNA at specific times during treatment, which helps guide clinical decision making 
throughout treatment of chronic HCV infection. 
Additional evaluation laboratory tests are needed to monitor the disease progression in these 
patients.  These tests include:2,23,27,30  
• Genotype testing 
• Serum fibrosis panels 
• Liver biopsy 
• Basic laboratory tests including: 
o Serum aminotransferase activity 
o Measures of synthetic function: Bilirubin, prothrombin time, and albumin 
o Complete blood count 
o Renal function, glucose, lipid panel, thyroid function tests 
o Urinalysis 
o 25-hydroxy vitamin D 
o Pregnancy test for women of childbearing potential 
  
Treatment Options for Chronic Hepatitis C Infection Genotype 1  
The goal of treatment in patients with chronic HCV infection is permanent eradication of HCV-
RNA which is shown by SVR, which is defined as absence of HCV-RNA by polymerase chain reaction for 
three to six months after stopping treatment.31 This is coupled with the permanent normalization of 
aminotransferase and cessation of histologic progression.2 Attaining an SVR has been associated with 
decreases in all-cause mortality, liver-related death, need for liver transplantation, hepatocellular 
carcinoma rates, and other liver-related complications.30,32 All patients with virologic evidence of chronic 
HCV should be considered for treatment, however, the evaluation and selection of patients for antiviral 
therapy is determined based upon history, physical exam, laboratory values, and noninvasive 
assessment of liver fibrosis.30,32 Liver biopsies are only done in select patients with HCV infection, these 
include: liver transplant, suspected autoimmune liver disease, drug induced liver disease, and in those 
with which the diagnosis is doubtful.30,32  
Until late 2013, all genotypes were treated with pegylated INF-alpha plus ribavirin; however, now 
patients are being treated with antiviral drugs that specifically target HCV.  Each HCV genotype can be 
treated differently with variable combinations of drug therapy.  Common direct-acting antiviral (DAA) 
medications are shown in Table 3.2  
 
Table 3. Direct Acting Antiviral Medications used to Treat HCV 
● Telaprevir and boceprevir: 1st-generation protease inhibitors with activity against HCV 
genotype 1 
● Simeprevir: A 2nd-generation genotype 1–specific protease inhibitor 
●  Sofosbuvir: A polymerase inhibitor with activity against HCV genotypes 1 to 6 
●  Paritaprevir: A protease inhibitor 
●  Ledipasvir: A protease inhibitor 
●  Dasabuvir: A polymerase inhibitor 
● Ombitasvir: An inhibitor of the viral nonstructural protein 5A 
 
Deciding when and whom to treat is mainly based off the presence of contraindications 
associated with the available treatment regimens.  Those who are candidates for antiviral therapy such 
as, Ledipasvir/Sofosbuvir (Harvoni ®)2,33, should be further assessed by evaluating the following labs: 
renal function, complete blood count with differential, concurrent alcohol or drug use, extrahepatic 
manifestations of HCV infection, HIV coinfection, presence of severe comorbidity, potential drug 
interactions.33  
  This study focuses on the treatment of chronic hepatitis C viral infection using 
ledipasvir/sofosbuvir (Harvoni ®).  Below consists of compiled information discussing the medication’s 
mechanism of action, indications, clinical use, contraindications, and adverse reactions. 
 
 
 
Mechanism of Action 
Ledipasvir/Sofosbuvir (Harvoni ®) is a combination antiviral drug that includes ledipasvir and sofosbuvir.  
Ledipasvir is an HCV NS5A protein inhibitor and Sofosbuvir is a prodrug converted to its 
pharmacologically active form that inhibits NS5B RNA-dependent RNA polymerase, both of which are 
essential for viral replication.33  
 
Indications: Treatment of chronic hepatitis C genotype 1 in both treatment naïve and treatment-
experienced patients.  The treatment duration is dependent on prior treatment and cirrhosis.  
• Genotype 1 treatment-naïve patients with or without cirrhosis: 12 weeks 
• Genotype 1 treatment-experienced patients without cirrhosis: 12 weeks 
• Genotype 1 treatment-experienced patients with cirrhosis: 24 weeks 
o Treatment experience is defined as patients who have failed treatment with either 
peginterferon plus ribavirin or peginterferon plus ribavirin plus a HCV protease inhibitor. 
o Note: Treatment duration of 8 weeks can be considered in treatment-naive patients 
without cirrhosis who have a baseline HCV RNA level less than 6 million IU/mL. 
 
Clinical Use 
Harvoni ® has been identified as an interferon free combination regimen for the treatment of treatment-
naïve and treatment-experienced patients with genotype 1 chronic HCV infection.  Phase 3 studies have 
consistently shown SVR rates greater than 90% with a 12-week course of Ledipasvir/Sofosbuvir (Harvoni 
®).33   
Contraindications 
There are currently no contraindications listed in the manufacturer’s U.S. labeling, however, Canadian 
labeling states a hypersensitivity to any component of the formulation.  There are warnings and 
precautions with this medication that include drug-to-drug interactions with specifically potent P-gp 
inducers (eg, rifampin, St. John’s wort) or amiodarone.  It is also advised to avoid using this drug 
concurrently with other sofosbuvir containing products.33,34  
 
Adverse Reactions 
These reactions are also seen with the individual components of Ledipasvir/Sofosbuvir (Harvoni ®).33,34  
• Central Nervous System: fatigue, headache, insomnia 
• Gastrointestinal: nausea, diarrhea, increased serum lipase 
• Hepatic: hyperbilirubinemia  
 
METHODS 
Patient Population 
 This is a pilot study is a collaboration between James Madison University (JMU) and the 
Harrisonburg-Rockingham Free Clinic (HRFC). JMU Physician Assistant students Caitlin Johnson and 
Jamie Taylor worked closely with Sharon Maiewski, PA-C, Susan Adamson, FNP, and Janice Gandy, RN 
of the HRFC to gather data, determine inclusion-exclusion criteria, and generate protocols.  
 Patients were enrolled in this study beginning May 15, 2015 in the United States. The duration of 
this study has yet to be determined, and is dependent on preliminary results and number of participating 
patients. Eligible patients were 18 years or older with chronic HCV genotype 1. Full inclusion and 
exclusion criteria are detailed in (Table 4). 
 
 
 
 
Table 4. Study inclusion and exclusion criteria for patient selection. 
Inclusion Criteria Exclusion Criteria 
● Confirmed Hepatitis C Virus Infection 
● Genotype 1a or 1b 
● Males and females ≥ 18 years of age 
● Subject able to comply with treatment 
requirements, monitoring requirements, and 
reduction of risk factors following treatment 
completion. 
● Patient of the Harrisonburg-Rockingham Free 
Clinic 
● Pregnant or Nursing 
 
Study Design and Assessments 
 In this single center prospective cohort study patients received care from the Harrisonburg-
Rockingham Free Clinic, and are administered a fixed-dose combination table containing 90mg of 
ledipasvir and 400mg of sofosbuvir (LDV-SOF) administered orally once a day for three months. 
Assessments during treatment included standard laboratory testing, vital signs, and symptom directed 
physical examinations. Complete blood counts, liver function tests, and HCV RNA levels were obtained 
before and after treatment with LDV-SOF (Table 5). An AST to Platelet Ratio Index (APRI) was calculated 
and included for evaluation as a viable measure of liver fibrosis or cirrhosis. In a meta-analysis of 40 
studies it was concluded that an APRI score greater than 1.0 had a sensitivity of 76% and a specificity of 
72% for predicting cirrhosis, and a score greater than 0.7 had a sensitivity of 77% and specificity of 72% 
for predicting hepatic fibrosis (http://www.ncbi.nlm.nih.gov/pubmed/19034235). 
  
Table 5. Laboratory and follow-up protocol for study participants taking LDV-SOF. CBC, complete blood 
count; LFT, liver function tests including AST/ALT; HCV-RNA measures viral load.  
 
Weeks following treatment Laboratory evaluation 
2 weeks CBC, LFT 
4 weeks CBC, LFT, HCV-RNA 
5 weeks Follow up with Free Clinic Provider 
8 weeks CBC, LFT 
12 weeks CBC, LFT, HCV-RNA 
24 weeks HCV-RNA 
 
 
 
 
 
 
 
Study Oversight 
 This trial did not require oversight or approval by the institutional review board or independent 
ethics committees. All patient identifiers were removed by Harrisonburg-Rockingham Free Clinic 
providers prior to use by researchers and it was determined that this population did not qualify as 
vulnerable. The primary efficacy endpoint was an HCV RNA level of less than 15 IU per milliliter at 12 
weeks after the end of therapy. 
  
Statistical Analysis 
 To grossly evaluate statistical significance between laboratory evaluations prior to, during, and 
following administration of LDV-SOF a t-test was used. Data was compiled in Microsoft Excel and 
statistical analysis was performed using this program. Currently sample size is small at 10 patients. As 
sample size and statistical power increases other statistical analysis methods will be considered to better 
assess overall differences between groups.  
 
RESULTS 
Patient Demographics 
 Of the 10 patients who underwent treatment with LDV-SOF for 12-weeks 30% of the patients are 
female and 70% are male. 89% of patients are white, and 11% of patients are black. 100% of patients 
have been diagnosed with hepatitis C genotype 1a infection. Due the patient population, comorbid 
conditions were fairly common. It was decided that these conditions would not be considered in 
evaluation of the data or statistical analysis. We would consider the contraindications issued by the 
manufacturer which only apply to coadministration with ribavirin.33  
 
Treatment Efficacy 
 Complete patient data is detailed in Appendix A. All patients received 12 weeks of LDV-SOF for 
12-weeks and were monitored according to the protocol outlined in Table 5. Patients are in various stages 
of treatment, and this complicates statistical analysis. Preliminary data supports a significant decrease, p-
values less than 0.05, in AST and ALT values 30 days following treatment initiation with LDV-SOF (Figure 
1 and 2). Total patient number in this group is 8. When following AST, significant changes were also seen 
60 days following treatment initiation where total patient number was 6 (Figure 1). 
 
 
                       
Figure 1. Average AST values before (n = 8), 30 days after (n=8), and 60 days after 
ledipasvir-sofosbuvir (90mg/400mg) treatment initiation (n=5). Double stars represent a p-
value less than 0.01, single star represents p-values less than 0.05.  
 
                 
Figure 2. Average ALT values before (n = 8), 30 days after (n=8), 60 days after (n=5), and 
after completion of ledipasvir-sofosbuvir (90mg/400mg)  treatment initiation (n=2). Single star 
represents p-values less than 0.05.  
  
 HCV-RNA levels responded quickly to treatment with LDV-SOF, with 40% of patients 
demonstrating undetectable viral loads 30 days after treatment initiation. After 30-60 days of treatment 
60% of patients demonstrated an undetectable viral load. This decrease in HCV-RNA levels is highly 
statistically significant, with a p-value less that 0.01 (Figure 3). Total patient number in the group was 6. 
 
0
20
40
60
80
100
120
140
160
180
Before 30 days after 60 days after After
AL
T 
vl
ue
s 
(U
/L
)
Days in relation to treatment
Clinical significance of ALT values
0
20
40
60
80
100
120
140
Before 30 days after 60 days after
AS
T 
va
lu
e 
(U
/L
)
Days in relation to treatment
Clinical significance of AST values
                    
Figure 3. Average HCV RNA values before (n = 5), and 30-60 days after ledipasvir-sofosbuvir 
(90mg/400mg) treatment initiation (n=5). Double stars represent a p-value less than 0.01.  
  
 Although liver biopsy is recognized as the gold standard for liver fibrosis staging, the AST to 
platelet ratio index (APRI) has been proposed and validated as a noninvasive and moderately accurate 
indicator of fibrosis of cirrhosis in patients with chronic liver disease.35 APRI ratios were calculated for 
study participants receiving 12-weeks of LDV-SOF (Figure 4). However, not enough data is available to 
perform statistical analysis and determine whether these patients had significant decreases in APRI ratios 
following treatment. Data will continue to be gathered to assess the appropriateness of the APRI for 
noninvasive evaluation of liver fibrosis in chronic HCV patients treated with LDV-SOF. 
 
 
 
                    
Figure 4. AST to platelet ratio index (APRI) before (red) and after (blue) treatment with 12 weeks of 
ledipasvir-sofosbuvir (90mg/400mg). APRI greater than 1.5 is highly suggestive of cirrhosis. 
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DISCUSSION 
Study purpose 
 HCV infection is responsible for approximately 40% of all chronic liver disease in the United 
States and HCV-associated cirrhosis is the most common indication for liver transplantation among 
adults.36 Until recently the majority of patients infected with hepatitis C virus were treated with 
recombinant human interferon (INF) alpha and ribavirin achieving a “cure” rate of approximately 60%.37  
These previous treatment regimens are associated with numerous side effects and often seriously impact 
patient’s quality of life.37 Recently, novel antiviral drugs like LDV-SOF, that specifically target HCV have 
provided better options in HCV treatment. Future use of these drugs has the potential to not only 
decrease the number of patients living with chronic HCV, but also reduce healthcare costs associated 
with treatment of complications of chronic HCV.  
 
Study Analysis 
 In published randomized control trials LDV-SOF is able to achieve a sustained viral response 
(SVR) representing undetectable levels of HCV-RNA after 12-weeks of treatment.37,38 A similar level of 
efficacy is seen in this study as well, with 100% of patients treated with 12-weeks of LDV-SOF achieving 
a SVR. However, it is important to note that our study is not yet able to evaluate whether the SVR is 
maintained months to years following treatment completion. Afdal et. al documents approximately 1/214 
(less than 1%), and Kowdley et al records 3/216 (1.4%) patients experiencing relapse following 
completion of treatment with LDV-SOF.37,38 In both studies HCV-relapse was associated with a NS5A 
resistant genotype as determined by deep gene sequencing.37,38 This data suggests there may be an 
indication for sequencing of HCV genome prior to LDV-SOF treatment, especially if cost is a factor.  
A major issue with the LDV-SOF medication and other similar treatment regimens is cost. 
Currently, the cost of 12-weeks of LDV-SOF costs patients without insurance $1,000-a –pill or $94,500 for 
12-weeks of treatment.39 This is further complicated by clinical observation that insurance companies 
require documented levels of fibrosis in patients in order to qualify LDV-SOF drug coverage. Cost and 
insurance requirements seriously inhibit the availability of these medications. The HRFC provides a 
unique population for study since all patients currently receiving treatment have qualified for the Support 
Path Patient Assistant Program, allowing them access to medication at no charge. These patients do not 
have to meet insurance requirements for treatment coverage, and therefore may represent a population 
receiving treatment with LDV-SOF that may have less liver damage associated with chronic HCV 
infection.   
 
Future study directions 
The major goal of this study is to assess long-term efficacy of LDV-SOF treatment for chronic 
HCV infection. This study is unique in that it is highly inclusive, assessing efficacy in newly diagnosed 
patients, previously treated patients, and patients with significant comorbidities affecting liver function and 
health. We would like to continue to gather data and increase the number of participants included in the 
study, with a final goal of 50 participants.  These patients will be continuously followed and assessed for 
evidence of treatment failure and HCV relapse. Also to be included in this study are patient surveys that 
would assess perceived quality of life before and following treatment, and include information about 
adverse effects experience while on LDV-SOF treatment regimen. Currently, no study participants have 
disclosed adverse events associated with treatment, and have been compliant with medication 
administration. The health related quality of life in patients with chronic liver disease (HRQL-CLD) 
questionnaire has been validated as a reliable measure of liver disease severity and has been suggested 
for use in this study.40 Together, this information will help the Harrisonburg-Rockingham Free Clinic gather 
data for continued participation in programs that reduce the cost of LDV-SOF and give patients in need 
the chance to live without chronic HCV infection.  
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